Characteristics of the patients lost to follow up compromise the generalization of our results.
Participant non-adherence and loss to follow-up can compromise the validity of clinical trial results.
Adherence and retention in clinical trials are important issues because participant non-adherence and loss to follow-up can compromise study results.
Although in most long-term studies loss to follow-up may compromise the integrity and interpretation of study results, the follow-up in DCCT and subsequently in EDIC has been virtually complete.
Care plans that place burdens on patients may result in a reduced willingness to return for follow-up and compromise the quality of the data obtained that is subsequently relied on during management.
As loss to follow-up can compromise the validity of findings from randomised trials, delay results and potentially increase trial costs, we conducted a systematic review to assess the effect of strategies to improve retention in randomised trials.
There are a few indications for which mammographic stereotactic biopsy of BIRADS III lesions may be considered, such as when follow-up is compromised or not available, in the instance of planned pregnancy, or for patient anxiety [ 27, 36– 36].
Therefore, because loss to follow-up can compromise the validity of a trial's findings, delay results and, in some circumstances, increase the costs of the research, a systematic review is needed to assess the effect of strategies to improve retention in randomised trials.
Inadequate duration of follow-up or treatment compromises the external validity of an RCT.
Incomplete data as well as a short follow-up may have compromised the results.
